Skip to main content

Table 5 Subgroup analyses for the relationship between mTOR/p-mTOR expression and OS of patients with ESCC

From: Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis

Subgroups N No. samples Heterogeneity (I2, p) Model HR with 95 % CI P value Conclusion
Total PE NE
Subgroups stratified by statistical analysis
Multivariate analysis 4 533 283 250 I2 = 26.0 %, p = 0.255 Fixed 2.071 (1.557–2.753) <0.001 Significant
Univariate analysis 2 180 98 82 I2 = 0.0 %, p = 0.592 Fixed 1.915 (1.114–3.292) 0.019 Significant
Subgroups stratified by cut-off values
10 % staining 3 325 174 151 I2 = 0.0 %, p = 0.731 Fixed 2.577 (1.788–3.714) <0.001 Significant
Non-10 % staining 3 388 207 181 I2 = 0.0 %, p = 0.694 Fixed 1.644 (1.160–2.328) 0.005 Significant
Subgroups stratified by follow-up periods
≥ 5-year OS 5 565 287 278 I2 = 9.2 %, p = 0.354 Fixed 2.037 (1.542–2.689) <0.001 Significant
< 5-year OS 1 148 94 54 –––– –––– 2.033 (1.117–3.701) 0.020 Significant
Subgroups stratified by positive-staining sites
Cytoplasm 4 473 268 205 I2 = 0.0 %, p = 0.785 Fixed 2.416 (1.769–3.301) <0.001 Significant
Nucleus or membrane Given up because of the scarcity of available data
  1. CI confidence interval, ESCC esophageal squamous cell carcinoma, HR hazard ratio, mTOR Mammalian Target of Rapamycin, N reference count, NE negative expression, OS overall survival, PE positive expression, p-mTOR Phosphorylated Mammalian Target of Rapamycin